Ozempic Litigation Comprehensive Guide: August 2025 Updates

Court Rulings Set Diagnostic Standards in GLP-1 Litigation

Judge Karen Spencer Marston's August 15, 2025 rulings in MDL 3094 established objective evidentiary requirements for plaintiffs alleging gastroparesis from GLP-1 receptor agonists.

August 15, 2025: Gastroparesis Evidentiary Order

Judge Marston issued two rulings defining proof standards for pending claims:

1. Objective Diagnostic Testing Requirement

• Plaintiffs claiming gastroparesis must present diagnostic confirmation from a gastric emptying study.
• Accepted modalities include gastric scintigraphy, 13C-octanoic acid breath testing, or wireless motility capsule (WMC) monitoring.
• Treating physician clinical impressions without confirmatory diagnostic testing do not meet the evidentiary threshold.

2. Motion to Dismiss Determinations

• Design defect claims: Dismissed.
• Failure to warn claims: Survived dismissal.
• Marketing and labeling misrepresentation claims: Survived dismissal.

NAION Vision Loss Filings

Alongside gastrointestinal claims, plaintiffs have filed actions alleging Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION):

• 30+ plaintiffs petitioned for multicounty litigation consolidation in New Jersey state court.
• Claims allege semaglutide reduces perfusion to the optic nerve head, resulting in sudden, permanent vision loss.
• Published observational studies have identified elevated NAION incidence among semaglutide patients compared to cohorts on alternative diabetes treatments.
• Current drug labeling does not include specific warnings regarding ischemic optic neuropathy.

MDL 3094 Case Schedule

Case management orders establish the following procedural timeline:

Claim Tiers and Valuation Framework

Valuation models correlate directly with objective medical verification:

Medical Documentation Requirements in GLP-1 Claims

Because court orders mandate specific diagnostic proof, locating and organizing clinical documentation is central to case evaluation.

Key Evidentiary Requirements

Operational Obstacles in GLP-1 Document Review

Mass tort practices encounter recurring operational hurdles:

1. Locating Buried Diagnostic Studies: Gastric emptying reports often reside within hospital radiology systems rather than standard primary care charts.
2. Multiple Treating Specialists: Patients typically visit endocrinologists, primary care doctors, gastroenterologists, and emergency departments.
3. Pre-Existing Symptom Histories: Defense discovery focuses heavily on pre-exposure nausea, reflux, and diabetic neuropathy notes.
4. Administrative Costs: Manual page-by-page review slows case qualification and increases overhead.

Processing GLP-1 Medical Records at Volume

Firms handling substantial GLP-1 dockets use specialized record retrieval and clinical review workflows to identify qualifying diagnostic records:

Operational Benefits for Litigation Teams

Standardized retrieval and clinical extraction provide clear operational advantages:

Strategic Priorities for Active Dockets

With extensive case inventories under evaluation, firms focus on four procedural steps:

1. Targeted Testing Audits: Screen files to isolate confirmed 4-hour gastric scintigraphy or wireless capsule studies.
2. NAION Record Discovery: Retrieve baseline ophthalmology records to establish pre-exposure visual acuity and subsequent optic nerve pathology.
3. Treatment Gap Identification: Identify unlisted treating gastroenterologists and imaging centers.
4. Disbursement Tracking: Route retrieval fees through itemized per-case accounting for post-settlement recovery.

Preparing GLP-1 Inventories for Bellwether Trials

As federal MDL 3047 and state dockets approach trial settings, case outcomes will depend on documented clinical evidence:

LlamaLab Retrieval for GLP-1 Dockets

LlamaLab supports law firms managing high-volume GLP-1 inventories:

• Fast Turnaround: Records returned in 4 days on average, with ~30-40% returned same-day on electronic requests.
• Clinical Evidence Extraction: Locates gastric emptying studies, transit times, retention percentages, and ophthalmology visual field tests.
• Reverse Provider Search: Uses insurance data to fill in treatment gaps clients don't always remember, surfacing facilities, dates, and clinicians as needed.
• Recoverable Accounting: Itemized per-case invoice that flows through as a recoverable case disbursement on settlement statements.

This article provides general information regarding Ozempic and GLP-1 litigation developments and should not be construed as legal advice. Consult qualified legal counsel for advice on specific matters.

Sources: Court filings and case management orders in MDL 3094 and related state court dockets.